[A retrospective study of tegafur/uracil compared with cyclophosphamide, methotrexate, and fluorouracil as adjuvant chemotherapy in patients with node-negative, triple-negative breast cancer].

Japanese clinical trials of a tegafur/uracil(UFT)-based postoperative chemotherapy regimen compared with cyclophosphamide, methotrexate, and fluorouracil(CMF)treatment have shown that UFT is not inferior to CMF for the treatment of hormone receptor-positive breast cancer patients. However, the usefulness of UFT for hormone receptor-negative breast cancer, including the triple-negative subtype(hormone receptor-negative, human epidermal growth factor receptor 2 [HER2]-negative), is unknown. The aim of this retrospective study was to examine the effectiveness of postoperative, adjuvant UFT compared to CMF when these regimens were given to women with node-negative, triple-negative breast cancer. We analyzed 50 women with node-negative, triple-negative breast cancer who were treated with six cycles of CMF(n=33) or two years of UFT(n=17)after surgery between January 2000 and December 2010. Although no significant differences were observed in relapse-free survival or overall survival in all patients, subset analysis of tumors of larger size(t2), higher nuclear grade(NG3), and with positivity for lymphovascular invasion showed that UFT was inferior to CMF. These results encourage caution regarding the choice of adjuvant UFT for node-negative, triple-negative breast cancer.